The Sarcoma Biology and Outcome Project

Studien-Informationen Einschlusskriterien Studien-Rationale

Rekrutierend

NCT-Nummer:
NCT04758325

Studienbeginn:
Juli 2019

Letztes Update:
14.08.2023

Wirkstoff:
-

Indikation (Clinical Trials):
Sarcoma, Mesenchymoma

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
Prof. Dr. Richard F Schlenk

Collaborator:
-

Studienleiter

Richard F. Schlenk, Prof.Dr.med
Principal Investigator
National Center for Tumour Disease

Christoph E. Heilig, Dr. med.
Study Director
National Center for Tumour Disease

Stefan Fröhling, Prof. Dr.
Study Director
National Center for Tumour Disease

Kontakt

Richard F. Schlenk, Prof.Dr.med
Kontakt:
Phone: +49 6221 56 6228
E-Mail: richard.schlenk@med.uni-heidelberg.de» Kontaktdaten anzeigen

SarcBOP Team
Kontakt:
E-Mail: sarcbop@nct-heidelberg.de» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

National Center for Tumour Diseases, University Hospital Heidelberg
69120 Heidelberg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Editha Gnutzmann, M.A.
Phone: +49 6221 5636235
E-Mail: editha.gnutzmann@med.uni-heidelberg.de

SarcBOP Team
E-Mail: sarcbop@nct-heidelberg.de» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

The following data are collected and stored:

- Demographics

- Comorbidities

- Clinical characteristics at diagnosis, relapse and progression

- Radiologic images

- Histological images

- Treatments including DRG and OPS data, including detailed information on surgical,

radiation, and medical therapy as well as treatment relevant follow-up data

- Longitudinal disease assessments

- Clinical outcome

- Genomic, transcriptomic, epigenomic and proteomic data

- Patient reported outcomes

Furthermore, biological samples are collected and processed by the Sample Processing

Laboratory of the Heidelberg Center for Personalized Oncology and the NCT Biobank.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Suspected or proven diagnosis of soft-tissue or bone sarcoma (STBS)

- Age ≥12 years

- Ability to understand nature and individual consequences of the registry

- Written informed consent

- Subjects who are physically or mentally capable of giving consent

Exclusion Criteria:

• Severe neurological or psychiatric disorder interfering with the ability to give written

informed consent

Studien-Rationale

Primary outcome:

1. overall survival (Time Frame - 5 years):
The length of time from the date of diagnosis disease, that patients diagnosed with are still alive

2. overall survival (Time Frame - 10 years):
The length of time from the date of diagnosis disease, that patients diagnosed

Secondary outcome:

1. progression free survival (Time Frame - 5 years):
length of time during and after treatment, that a Patient lives with the disease without getting worse

Quelle: ClinicalTrials.gov

Sie können folgenden Inhalt einem Kollegen empfehlen:

"The Sarcoma Biology and Outcome Project"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!